Synlogic, Inc.
SYBX Healthcare Biotechnology
Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow SYBX
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
(3.23) | (1.00) | (0.64) | (0.65) |
Non Cash Items (Other) |
(0.10) | (2.27) | (3.12) | (3.36) | |
Change in payables and accrued liability |
(0.97) | (1.18) | 0.34 | 0.12 | |
Change in other assets and liabilities |
0.29 | 0.10 | 0.10 | 0.05 | |
Operating Cash Flow |
(4.00) | (4.36) | (3.32) | (3.84) | |
Capital expenditures |
0.20 | 0.17 | — | — | |
Investing cash flow |
0.20 | 0.17 | — | — | |
Financing cash flow |
— | — | — | — | |
Change in Cash |
(3.80) | (4.19) | (3.17) | (3.84) | |
Beginning Cash |
18.91 | 18.91 | 14.72 | 14.72 | |
Ending Cash |
15.11 | 14.72 | 11.55 | 10.87 | |
Stock Based Compensation |
0.44 | 0.12 | 0.10 | 0.08 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(0.68) | (1.08) | 0.44 | 0.17 |